Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares rose 7.7% during trading on Tuesday . The stock traded as high as $10.98 and last traded at $10.33. Approximately 1,402,689 shares changed hands during mid-day trading, an increase of 150% from the average daily volume of 560,183 shares. The stock had previously closed at $9.59.

COLL has been the subject of several recent research reports. Piper Jaffray Companies set a $14.00 price objective on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, July 25th. Jefferies Group LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Finally, HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a research note on Monday, September 11th. They issued a “buy” rating and a $21.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Collegium Pharmaceutical has an average rating of “Hold” and a consensus price target of $20.00.

The company’s 50-day moving average is $10.82 and its 200-day moving average is $10.81. The firm’s market capitalization is $305.42 million.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.09. The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. On average, equities research analysts expect that Collegium Pharmaceutical, Inc. will post ($3.00) EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American International Group Inc. boosted its holdings in Collegium Pharmaceutical by 27.8% in the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after acquiring an additional 2,163 shares during the period. Voya Investment Management LLC purchased a new position in Collegium Pharmaceutical in the 2nd quarter worth approximately $125,000. Nationwide Fund Advisors boosted its holdings in Collegium Pharmaceutical by 16.4% in the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 1,422 shares during the period. Credit Suisse AG boosted its holdings in Collegium Pharmaceutical by 9.4% in the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after acquiring an additional 1,173 shares during the period. Finally, UBS Group AG boosted its holdings in Collegium Pharmaceutical by 283.2% in the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after acquiring an additional 10,174 shares during the period. Hedge funds and other institutional investors own 83.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Collegium Pharmaceutical, Inc. (COLL) Stock Price Up 7.7%” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/10/31/collegium-pharmaceutical-inc-coll-stock-price-up-7-7.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.